Opportunity Information: Apply for RFA AI 19 072
This opportunity, titled "Novel Therapeutics Directed to Intracellular HIV Targets (R21 Clinical Trial Not Allowed)" (Funding Opportunity Number RFA-AI-19-072), is a National Institutes of Health (NIH) discretionary grant solicitation focused on early-stage research and development of new HIV treatments that act on targets inside infected cells. The central idea is that, during the HIV life cycle, infected cells produce multiple viral proteins that are essential for viral assembly, release, and maturation. Because each of these proteins has a specific, necessary function, the FOA encourages applicants to pursue therapeutic strategies that inhibit one or more intracellular, virus-associated proteins with the goal of achieving strong antiviral activity. In practical terms, the program is looking for innovative therapeutic concepts that go beyond existing approaches and directly interfere with the intracellular machinery HIV relies on to successfully replicate.
The mechanism is an R21, which typically supports exploratory or developmental projects that can establish feasibility, generate key proof-of-concept data, or open up a new line of investigation. The FOA explicitly states "Clinical Trial Not Allowed," meaning the proposed work must not include clinical trials; it is intended for preclinical, discovery, and development efforts rather than testing interventions in human participants. The funding activity category is Health, and the associated CFDA number is 93.855. The original closing date listed for this opportunity was July 1, 2020, and the FOA was created on December 19, 2019.
Eligibility is broad and includes many types of U.S.-based and certain non-U.S. organizations. Eligible applicants include state, county, city or township governments, special district governments, and independent school districts, as well as public and state-controlled institutions of higher education and private institutions of higher education. Tribal entities are also eligible, including federally recognized Native American tribal governments, and Native American tribal organizations that are not federally recognized tribal governments. The FOA also allows applications from public housing authorities/Indian housing authorities, nonprofit organizations with or without 501(c)(3) status (as long as they are not institutions of higher education), for-profit organizations other than small businesses, and small businesses. In addition, the announcement highlights other eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal government agencies, U.S. territories or possessions, regional organizations, and non-domestic (non-U.S.) entities (foreign organizations). Overall, the FOA is designed to attract a wide range of scientific teams and organizations capable of advancing new intracellularly targeted HIV therapeutic ideas through exploratory development and preclinical validation, without moving into clinical trial activity under this specific funding call.Apply for RFA AI 19 072
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Novel Therapeutics Directed to Intracellular HIV Targets (R21 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855.
- This funding opportunity was created on 2019-12-19.
- Applicants must submit their applications by 2020-07-01. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Novel Therapeutics Directed to Intracellular HIV Targets (R21 Clinical Trial Not Allowed)
What is the title of this funding opportunity?
The opportunity is titled "Novel Therapeutics Directed to Intracellular HIV Targets (R21 Clinical Trial Not Allowed)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA-AI-19-072.
Which agency is offering this grant?
This is a National Institutes of Health (NIH) discretionary grant solicitation.
What is the main purpose of this FOA?
The FOA supports early-stage research and development of new HIV treatments that act on targets inside infected cells. It emphasizes therapeutic strategies that inhibit one or more intracellular, virus-associated proteins that are essential for viral assembly, release, and maturation, with the goal of achieving strong antiviral activity.
What kind of scientific approach is the FOA encouraging?
The FOA encourages innovative therapeutic concepts that go beyond existing approaches and directly interfere with the intracellular machinery HIV relies on to successfully replicate, particularly by targeting intracellular viral proteins produced during the HIV life cycle.
What grant mechanism is being used?
The mechanism is an R21.
What does the R21 mechanism typically support?
R21 awards typically support exploratory or developmental projects intended to establish feasibility, generate key proof-of-concept data, or open up a new line of investigation.
Are clinical trials allowed under this FOA?
No. The FOA explicitly states "Clinical Trial Not Allowed," meaning proposed work must not include clinical trials or testing interventions in human participants under this specific solicitation.
What type of work is this FOA intended to fund if clinical trials are not allowed?
It is intended for preclinical, discovery, and development efforts focused on intracellularly targeted HIV therapeutic ideas, including exploratory development and preclinical validation, without moving into clinical trial activity.
What is the funding activity category?
The funding activity category is Health.
What is the associated CFDA number?
The associated CFDA number is 93.855.
When was this FOA created?
The FOA was created on December 19, 2019.
What was the original closing date listed for this opportunity?
The original closing date listed was July 1, 2020.
Who is eligible to apply in general?
Eligibility is broad and includes many types of U.S.-based organizations as well as certain non-U.S. organizations (foreign entities).
Are state and local governments eligible?
Yes. Eligible applicants include state governments, county governments, city or township governments, special district governments, and independent school districts.
Are colleges and universities eligible?
Yes. Eligible applicants include public and state-controlled institutions of higher education and private institutions of higher education.
Are Tribal entities eligible to apply?
Yes. Eligible applicants include federally recognized Native American tribal governments and Native American tribal organizations that are not federally recognized tribal governments.
Are nonprofit organizations eligible?
Yes. Eligible applicants include nonprofit organizations with or without 501(c)(3) status, as long as they are not institutions of higher education.
Are for-profit organizations eligible?
Yes. Eligible applicants include for-profit organizations other than small businesses, and small businesses.
Are public housing authorities eligible?
Yes. Public housing authorities/Indian housing authorities are listed as eligible applicants.
Are minority-serving institutions specifically mentioned as eligible?
Yes. The announcement highlights eligibility for Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are specifically listed among eligible applicant categories.
Are federal agencies eligible to apply?
Yes. Eligible federal government agencies are listed as eligible applicants.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are included among eligible applicant categories.
Are regional organizations eligible?
Yes. Regional organizations are listed as eligible.
Are non-U.S. (foreign) organizations eligible?
Yes. Non-domestic (non-U.S.) entities (foreign organizations) are included in the eligibility list.
What is the central biological rationale behind targeting intracellular HIV proteins?
The FOA emphasizes that infected cells produce multiple viral proteins during the HIV life cycle, and these proteins are essential for viral assembly, release, and maturation. Because each protein has a specific, necessary function, inhibiting one or more of these intracellular, virus-associated proteins is presented as a promising strategy to achieve strong antiviral activity.
What kinds of outcomes is the FOA aiming to enable at this early stage?
Based on the R21 focus and the FOA description, the aim is to support feasibility testing, proof-of-concept generation, and exploratory preclinical development for innovative intracellularly targeted HIV therapeutic strategies.
Browse more opportunities from the same category: Health
Next opportunity: Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
Previous opportunity: Ocean Freight Reimbursement Program FY2020 and FY2021
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 19 072
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 19 072) also looked into and applied for these:
| Funding Opportunity |
|---|
| Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed) Apply for PAR 20 078 Funding Number: PAR 20 078 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition 4DN Data Coordination and Integration Center (U01 Clinical Trial Not Allowed) Apply for RFA RM 20 008 Funding Number: RFA RM 20 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: 4DN Organizational Hub (U01 Clinical Trial Not Allowed) Apply for RFA RM 20 007 Funding Number: RFA RM 20 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Surgical Disparities Research (R01 - Clinical Trial Optional) Apply for PAR 20 079 Funding Number: PAR 20 079 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional) Apply for PAR 20 084 Funding Number: PAR 20 084 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed) Apply for PAR 20 037 Funding Number: PAR 20 037 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Animal and Biological Material Resource Centers (P40) (Clinical Trials Not-Allowed) Apply for RFA OD 20 002 Funding Number: RFA OD 20 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional) Apply for PAR 20 038 Funding Number: PAR 20 038 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| MoTrPAc Phase 2 Animal Studies (U01 Clinical Trial Not Allowed) Apply for RFA RM 20 009 Funding Number: RFA RM 20 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Infrastructure for the Expansion of Rhesus macaque Colonies to Support HIV/AIDS-related Research (C06 Clinical Trial Not Allowed) Apply for PAR 20 087 Funding Number: PAR 20 087 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Biomedical Research Facilities (C06 Clinical Trial Not Allowed) Apply for PAR 20 086 Funding Number: PAR 20 086 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mendelian Genomics Research Centers (U01 Clinical Trial Optional) Apply for RFA HG 20 007 Funding Number: RFA HG 20 007 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Central and Peripheral Control of Balance in Older Adults (R01 Clinical Trial Optional) Apply for RFA AG 21 011 Funding Number: RFA AG 21 011 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Mendelian Genomics Data Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA HG 20 008 Funding Number: RFA HG 20 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAMS Clinical Trial Planning Grant (R34) - Clinical Trial Not Allowed Apply for PAR 20 090 Funding Number: PAR 20 090 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Development of Research Education Resources for Geriatrics-Related Translational and Clinical Scientists (R25 Independent Clinical Trial Not Allowed) Apply for PAR 20 095 Funding Number: PAR 20 095 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional) Apply for PAR 20 093 Funding Number: PAR 20 093 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| NIMH Mentoring Networks for Mental Health Research Education (R25 Clinical Trial Not Allowed) Apply for PAR 20 080 Funding Number: PAR 20 080 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NIMH Research Education Programs for Psychiatry Residents (R25- Independent Clinical Trial Not Allowed) Apply for PAR 20 094 Funding Number: PAR 20 094 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Accelerating Medicine Partnership in Parkinsons disease (AMP PD) data use and analysis (U01 Clinical trials not allowed) Apply for RFA NS 20 027 Funding Number: RFA NS 20 027 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 19 072", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.